Complete financial analysis of Eiger BioPharmaceuticals, Inc. (EIGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eiger BioPharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Gala Incorporated (4777.T) Income Statement Analysis – Financial Results
- Renren Inc. (RENN) Income Statement Analysis – Financial Results
- PT Pradiksi Gunatama Tbk (PGUN.JK) Income Statement Analysis – Financial Results
- Bank of America Corporation (BML-PG) Income Statement Analysis – Financial Results
- Jack Creek Investment Corp. (JCICU) Income Statement Analysis – Financial Results
Eiger BioPharmaceuticals, Inc. (EIGR)
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.77M | 13.48M | 12.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 24.00K | 1.84M | 745.00K | 645.00K | 486.00K | 54.00K | 41.00K | 23.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.75M | 11.65M | 11.40M | -645.00K | -486.00K | -54.00K | -41.00K | -23.00K | -11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 99.85% | 86.38% | 93.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.33M | 75.28M | 64.44M | 41.59M | 51.79M | 37.09M | 29.52M | 33.01M | 21.96M | 22.68M | 16.93M | 13.31M | 4.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.20M | 29.11M | 23.90M | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Other Expenses | 87.00K | -963.00K | 46.49M | -12.00K | -15.00K | -12.00K | 186.00K | -277.00K | 5.00K | -835.00K | 25.00K | 147.00K | 152.00K |
| Operating Expenses | 87.54M | 104.39M | 88.34M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Cost & Expenses | 87.56M | 106.22M | 89.08M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Interest Income | 2.21M | 1.08M | 158.00K | 704.00K | 2.07M | 997.00K | 410.00K | 0.00 | 65.00K | 118.00K | 69.00K | 35.00K | 7.00K |
| Interest Expense | 5.47M | 4.13M | 3.56M | 3.59M | 3.41M | 2.33M | 1.52M | 690.00K | 2.30M | 741.00K | 59.00K | 108.00K | 1.12M |
| Depreciation & Amortization | 750.00K | 119.00K | 46.65M | 1.34M | 2.54M | 54.00K | 41.00K | 23.00K | 504.00K | 153.00K | 67.00K | 64.00K | 73.00K |
| EBITDA | -68.74M | -92.62M | -76.94M | -60.81M | -66.36M | -50.06M | -40.92M | -46.40M | -33.82M | -33.02M | -19.80M | -15.70M | -5.79M |
| EBITDA Ratio | -435.81% | -686.90% | -249.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.79M | -92.74M | -76.94M | -62.15M | -68.90M | -51.05M | -41.52M | -46.12M | -42.18M | -33.02M | -19.96M | -15.95M | -6.03M |
| Operating Income Ratio | -455.12% | -687.78% | -633.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.17M | -4.01M | 43.09M | -2.90M | -1.35M | -1.34M | -928.00K | -967.00K | -2.23M | -835.00K | -127.00K | 74.00K | -965.00K |
| Income Before Tax | -74.96M | -96.75M | -33.85M | -65.05M | -70.25M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.09M | -15.87M | -6.99M |
| Income Before Tax Ratio | -475.22% | -717.54% | -278.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 6.00K | 23.00K | 64.00K | 3.58M | 3.39M | 985.00K | 1.67M | 390.00K | 2.31M | -153.00K | -12.00K | 101.00K | 1.28M |
| Net Income | -74.96M | -96.78M | -33.92M | -68.63M | -73.64M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.00M | -15.72M | -6.99M |
| Net Income Ratio | -475.26% | -717.71% | -279.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| EPS Diluted | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| Weighted Avg Shares Out | 1.48M | 1.39M | 34.63M | 29.88M | 24.43M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
| Weighted Avg Shares Out (Dil) | 1.48M | 1.39M | 34.63M | 29.88M | 24.50M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
FDA Approves Eiger Biopharma's Progeria Treatment: What Investors Should Know
The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processing-deficient progeroid laminopathies. The Palo Alto, California-based company focuses on targeted therapies for serious rate and ultra-rare...
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience™ 2020
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-rare diseases, today announced a poster presentation of two case studies from the...
Stocks To Watch: Spotlight On Palo Alto Networks, Best Buy And Xpeng Motors
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
BidaskClub Lowers Eiger Biopharmaceuticals (NASDAQ:EIGR) to Strong Sell
BidaskClub cut shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) from a sell rating to a strong sell rating in a research report released on Friday morning, BidAskClub reports. Other research analysts have also recently issued research reports about the stock. Wedbush reiterated...
Coronavirus Pandemic: Regeneron And Eiger BioPharmaceuticals Positioned To Benefit From Opportunity In Treating Early Stage And At-Risk Patients
I have been discussing the idea that the tragic coronavirus pandemic presents a unique opportunity in which a healthcare event can lead to profitable investments.
Antivirals In The COVID-19 Space
A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Shares Purchased by Deutsche Bank AG
Deutsche Bank AG increased its stake in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 306.4% in the 1st quarter, HoldingsChannel reports. The firm owned 52,683 shares of the biotechnology company’s stock after purchasing an additional 39,720 shares during the period....
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Stake Raised by Nuveen Asset Management LLC
Nuveen Asset Management LLC boosted its holdings in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 196.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 234,665 shares of...
Source: https://incomestatements.info
Category: Stock Reports